Lower Dose of Mpox Vaccine Was Safe, Effective

Intradermal injections that were one-fifth of the standard mpox vaccine dose generated antibody responses equivalent to those of subcutaneous injections of the standard dose at 6 weeks, based on results from 225 US adults aged 18 to 50 years. No participants experienced serious adverse events related to the vaccine.